As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.
12 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:
12 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:
Jun '25 |
+/-
%
|
||
Revenue | 4,603 4,603 |
48%
48%
|
|
Gross Profit | 3,930 3,930 |
50%
50%
|
|
EBITDA | - - |
-
|
|
EBIT (Operating Income) EBIT | -100 -100 |
89%
89%
|
|
Net Profit | -232 -232 |
62%
62%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.
Head office | Cayman Islands |
CEO | John Oyler |
Employees | 11,000 |
Founded | 2010 |
Website | www.beigene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.